Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients: A propensity score matched analysis

Summary Background Remdesivir is the only antiviral agent approved for the treatment of hospitalized coronavirus disease 2019 (COVID-19) patients requiring supplemental oxygen. Studies show conflicting results regarding its effect on mortality. Methods In this single center observational study, we i...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Wiener Klinische Wochenschrift 2022-12, Vol.134 (23-24), p.883-891
Hauptverfasser:	Karolyi, Mario, Kaltenegger, Lukas, Pawelka, Erich, Kuran, Avelino, Platzer, Moritz, Totschnig, David, Koenig, Franz, Hoepler, Wolfgang, Laferl, Hermann, Omid, Sara, Seitz, Tamara, Traugott, Marianna, Arthofer, Sigrun, Erlbeck, Lea, Jaeger, Stefan, Kettenbach, Alina, Assinger, Alice, Wenisch, Christoph, Zoufaly, Alexander
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antiviral Agents - therapeutic use COVID-19 Endocrinology Female Gastroenterology Hospital Mortality Humans Internal Medicine Medicine Medicine & Public Health Original Article Pneumology/Respiratory System Propensity Score
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!